Zis A P, Goodwin F K
Arch Gen Psychiatry. 1979 Sep;36(10):1097-1107. doi: 10.1001/archpsyc.1979.01780100067006.
The introduction of two tricyclic compounds (iprindole and mianserin) that are reported to have antidepressant properties but to be relatively devoid of effects on central amine neurotransmitter systems has raised questions about the amine hypothesis of depression and about the mechanism of action of tricyclics in general. In view of the importance of these questions, a critical review of both the clinical and pharmacological profiles of iprindole and mianserin was undertaken. Iprindole is a relatively weak inhibitor of both norepinephrine (NE) and serotonin, whereas mianserin possesses at least modest potency as an inhibitor of NE uptake. However, the evidence is as yet insufficient to prove the superiority of iprindole over placebo in the treatment of those depressions characterized by endogenous symptoms. In considering the pharmacological profiles of these two drugs together with their clinical profiles, the data are not inconsistent with the hypothesized role of biogenic amines in major depression.
据报道，两种三环化合物（茚满二酮和米安色林）具有抗抑郁特性，但对中枢胺神经递质系统的影响相对较小，这引发了关于抑郁症胺假说以及三环类药物一般作用机制的问题。鉴于这些问题的重要性，对茚满二酮和米安色林的临床和药理学特征进行了批判性综述。茚满二酮是去甲肾上腺素（NE）和5-羟色胺的相对较弱抑制剂，而米安色林作为NE摄取抑制剂至少具有中等效力。然而，目前尚无足够证据证明茚满二酮在治疗以内源性症状为特征的抑郁症方面优于安慰剂。在综合考虑这两种药物的药理学特征及其临床特征时，这些数据与生物胺在重度抑郁症中的假设作用并不矛盾。
